Literature DB >> 33944612

NAMPT single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia.

Daniela A Pereira1, Valeria C Sandrim2, Ana C Palei3, Lorena M Amaral4, Vanessa A Belo1, Riccardo Lacchini5, Ricardo C Cavalli6, Jose E Tanus-Santos7, Marcelo R Luizon1,8.   

Abstract

Aim: We examined the relationships between visfatin/NAMPT and nitrite concentrations (a marker of nitric oxide [NO] formation) or sFlt-1 levels in 205 patients with preeclampsia (PE) responsive or nonresponsive to antihypertensive therapy, and whether NAMPT SNPs rs1319501 and rs3801266 affect nitrite concentrations in PE and 206 healthy pregnant women. Patients & methods: Circulating visfatin/NAMPT and sFlt-1 levels were measured by ELISA, and nitrite concentrations by using an ozone-based chemiluminescence assay.
Results: In nonresponsive PE patients, visfatin/NAMPT levels were inversely related to nitrite concentrations and positively related to sFlt-1 levels. NAMPT SNP rs1319501 affected nitrite concentrations in nonresponsive PE patients and was tightly linked with NAMPT functional SNPs in Europeans.
Conclusion: NAMPT SNP rs1319501 and visfatin/NAMPT affect NO formation, sFlt-1 levels and antihypertensive therapy response in PE.

Entities:  

Keywords:  antihypertensive agents; genetic polymorphisms; nicotinamide phosphoribosyltransferase; nitric oxide; pharmacogenetics; preeclampsia; sFlt-1; visfatin/NAMPT

Mesh:

Substances:

Year:  2021        PMID: 33944612      PMCID: PMC9552901          DOI: 10.2217/pgs-2021-0006

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.638


  59 in total

1.  Gene-gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.

Authors:  M R Luizon; A C T Palei; V A Belo; L M Amaral; R Lacchini; G Duarte; R C Cavalli; V C Sandrim; J E Tanus-Santos
Journal:  Pharmacogenomics J       Date:  2016-05-10       Impact factor: 3.550

2.  Pharmacogenomic approaches that may guide preeclampsia therapy.

Authors:  Marcelo R Luizon; Valeria C Sandrim
Journal:  Pharmacogenomics       Date:  2013-04       Impact factor: 2.533

3.  Mechanical stress induces pre-B-cell colony-enhancing factor/NAMPT expression via epigenetic regulation by miR-374a and miR-568 in human lung endothelium.

Authors:  Djanybek M Adyshev; Venkateswaran Ramamoorthi Elangovan; Nurgul Moldobaeva; Brandon Mapes; Xiaoguang Sun; Joe G N Garcia
Journal:  Am J Respir Cell Mol Biol       Date:  2014-02       Impact factor: 6.914

4.  Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.

Authors:  A C T Palei; V C Sandrim; L M Amaral; J S R Machado; R C Cavalli; R Lacchini; G Duarte; J E Tanus-Santos
Journal:  Pharmacogenomics J       Date:  2011-07-19       Impact factor: 3.550

5.  Nitric oxide production increases during normal pregnancy and decreases in preeclampsia.

Authors:  Jong Weon Choi; Moon Whan Im; Soo Hwan Pai
Journal:  Ann Clin Lab Sci       Date:  2002       Impact factor: 1.256

Review 6.  Vascular dysfunction in preeclampsia.

Authors:  Lesley J Brennan; Jude S Morton; Sandra T Davidge
Journal:  Microcirculation       Date:  2014-01       Impact factor: 2.628

7.  The NAMPT promoter is regulated by mechanical stress, signal transducer and activator of transcription 5, and acute respiratory distress syndrome-associated genetic variants.

Authors:  Xiaoguang Sun; Venkateswaran Ramamoorthi Elangovan; Brandon Mapes; Sara M Camp; Saad Sammani; Laleh Saadat; Ermelinda Ceco; Shwu-Fan Ma; Carlos Flores; Matthew S MacDougall; Hector Quijada; Bin Liu; Carrie L Kempf; Ting Wang; Eddie T Chiang; Joe G N Garcia
Journal:  Am J Respir Cell Mol Biol       Date:  2014-11       Impact factor: 6.914

Review 8.  Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease.

Authors:  Camille E Powe; Richard J Levine; S Ananth Karumanchi
Journal:  Circulation       Date:  2011-06-21       Impact factor: 29.690

9.  Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity.

Authors:  Susana Vallejo; Tania Romacho; Javier Angulo; Laura A Villalobos; Elena Cercas; Alejandra Leivas; Elena Bermejo; Raffaele Carraro; Carlos F Sánchez-Ferrer; Concepción Peiró
Journal:  PLoS One       Date:  2011-11-03       Impact factor: 3.240

10.  GeneHancer: genome-wide integration of enhancers and target genes in GeneCards.

Authors:  Simon Fishilevich; Ron Nudel; Noa Rappaport; Rotem Hadar; Inbar Plaschkes; Tsippi Iny Stein; Naomi Rosen; Asher Kohn; Michal Twik; Marilyn Safran; Doron Lancet; Dana Cohen
Journal:  Database (Oxford)       Date:  2017-01-01       Impact factor: 3.451

View more
  1 in total

Review 1.  Placental Ischemia Says "NO" to Proper NOS-Mediated Control of Vascular Tone and Blood Pressure in Preeclampsia.

Authors:  Ana C Palei; Joey P Granger; Frank T Spradley
Journal:  Int J Mol Sci       Date:  2021-10-19       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.